The biggest study in real conditions conducted in the United States on Beyfortus (Nirsevimab-Alip) Injection 50 mg and 100 mg successfully reached its two main evaluation criteria, demonstrating that Beyfortus offers babies against syncytial respiratory virus disease (VRS). The complete results of the study “Efficiency of the Norsevimab against the VRS and the events related to the VRS in infants” were published in PEDIATRICS®official review of the American Academy of Pediatrics. Led during the 2023-2024 VRS season, this study strengthens the widespread use of Beyfortus as a proven solution for prevention of VRS, designed to protect all infants, whether they were born in good health or with underlying pathologies, in the long term or premature, before or during the VRS season.
Beyfortus is a long-lasting monoclonal antibody, approved for the prevention of lower respiratory tract disease (LRTD) caused by the VRS in newborns and infants born during or entering their first season of VRS, as well as in children up to 24 months remaining vulnerable to a severe form of the disease during their second season of VRS. The first main criterion has shown that infants who received Beyfortus have seen their hospitalizations and reduced medical consultations by 87 %(CI: 81.7 %–91.1 %; p.2).
